ImageneBio director Steven Hui Wang resigns

Rhea-AI Filing Summary

FAQ

Filing Exhibits & Attachments

Q: What board change did ImageneBio (IMA) disclose in this 8-K?

Q: Did Steven Hui Wang’s resignation from ImageneBio (IMA) involve any disagreement?

Q: When did ImageneBio (IMA) say Steven Hui Wang’s resignation became effective?

Q: Who signed the ImageneBio (IMA) 8-K reporting the board resignation?

Q: On which exchange is ImageneBio (IMA) common stock listed?

Q: What type of SEC filing did ImageneBio (IMA) use to report the resignation?

8-K Event Classification

What board change did ImageneBio (IMA) disclose in this 8-K?

Did Steven Hui Wang’s resignation from ImageneBio (IMA) involve any disagreement?

When did ImageneBio (IMA) say Steven Hui Wang’s resignation became effective?

Who signed the ImageneBio (IMA) 8-K reporting the board resignation?

On which exchange is ImageneBio (IMA) common stock listed?

What type of SEC filing did ImageneBio (IMA) use to report the resignation?

ImageneBio reported that director Steven Hui Wang resigned from its Board of Directors, effective February 12, 2026. The company emphasized that his resignation was not due to any disagreement with its operations, policies, practices, or strategy.

The company stated that Steven Hui Wang’s resignation was not the result of any disagreement with ImageneBio. This includes no dispute regarding the company’s operations, policies, practices, or overall strategy as described in the filing.

ImageneBio disclosed that Steven Hui Wang’s resignation from the Board of Directors became effective immediately on February 12, 2026. That date is identified in the report as the earliest event reported for this filing.

The report was signed on behalf of ImageneBio by Kristin Yarema, Ph.D., the company’s Chief Executive Officer. Her electronic signature appears with a date of February 17, 2026, authorizing the submission of the current report.

ImageneBio’s common stock, with a par value of $0.001 per share, is listed on The Nasdaq Capital Market. The filing specifies that the company’s shares trade under the ticker symbol IMA on that exchange.

ImageneBio used a Form 8-K current report to disclose the resignation of director Steven Hui Wang. Form 8-K is used to inform investors about significant corporate events between regular quarterly and annual reports.

ImageneBio, Inc. reported that Steven Hui Wang resigned from its Board of Directors, effective immediately on February 12, 2026.

Accepted by SEC EDGAR 02/17/2026 - 04:15 PM EST

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

ImageneBio, Inc. reported that Steven Hui Wang resigned from its Board of Directors, effective immediately on February 12, 2026. The company stated that his resignation was not due to any disagreement with ImageneBio regarding its operations, policies, practices, or strategy. The filing otherwise reflects routine corporate and listing information, including that ImageneBio’s common stock trades on the Nasdaq Capital Market under the symbol IMA.

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

ImageneBio reported that director Steven Hui Wang resigned from its Board of Directors, effective February 12, 2026. The company emphasized that his resignation was not due to any disagreement with its operations, policies, practices, or strategy.

The company stated that Steven Hui Wang’s resignation was not the result of any disagreement with ImageneBio. This includes no dispute regarding the company’s operations, policies, practices, or overall strategy as described in the filing.

ImageneBio disclosed that Steven Hui Wang’s resignation from the Board of Directors became effective immediately on February 12, 2026. That date is identified in the report as the earliest event reported for this filing.

The report was signed on behalf of ImageneBio by Kristin Yarema, Ph.D., the company’s Chief Executive Officer. Her electronic signature appears with a date of February 17, 2026, authorizing the submission of the current report.

ImageneBio’s common stock, with a par value of $0.001 per share, is listed on The Nasdaq Capital Market. The filing specifies that the company’s shares trade under the ticker symbol IMA on that exchange.

ImageneBio used a Form 8-K current report to disclose the resignation of director Steven Hui Wang. Form 8-K is used to inform investors about significant corporate events between regular quarterly and annual reports.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 12, 2026

IMAGENEBIO, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-40287

81-1697316

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(I.R.S. Employer

Identification No.)


12526 High Bluff Drive, Suite 345
San Diego, California		92130
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (858) 345-6265

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading
Symbol(s)

Name of each exchange

on which registered

Common Stock, $0.001 par value

IMA

The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On February 12, 2026, Steven Hui Wang resigned as a member of the Board of Directors (the “Board”) of ImageneBio, Inc. (the “Company”), effective immediately.

Mr. Wang’s resignation was not the result of any disagreement with the Company on any matter related to the Company’s operations, policies, practices or strategy.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Source: View Original Filing on SEC EDGAR

IMAGENEBIO, INC.

Date: February 17, 2026

/s/ Kristin Yarema

Kristin Yarema, Ph.D.

Chief Executive Officer

3 documents